These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 16565432)

  • 1. Bacteriophage endolysins as a novel class of antibacterial agents.
    Borysowski J; Weber-Dabrowska B; Górski A
    Exp Biol Med (Maywood); 2006 Apr; 231(4):366-77. PubMed ID: 16565432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections.
    Gondil VS; Harjai K; Chhibber S
    Int J Antimicrob Agents; 2020 Feb; 55(2):105844. PubMed ID: 31715257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria.
    Gerstmans H; Rodríguez-Rubio L; Lavigne R; Briers Y
    Biochem Soc Trans; 2016 Feb; 44(1):123-8. PubMed ID: 26862197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy.
    Oliveira H; São-José C; Azeredo J
    Viruses; 2018 May; 10(6):. PubMed ID: 29844287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lysis of bacterial cells in the process of bacteriophage release--canonical and newly discovered mechanisms].
    Woźnica WM; Bigos J; Łobocka MB
    Postepy Hig Med Dosw (Online); 2015 Jan; 69():114-26. PubMed ID: 25614679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriophages, phage endolysins and antimicrobial peptides - the possibilities for their common use to combat infections and in the design of new drugs.
    Mirski T; Lidia M; Nakonieczna A; Gryko R
    Ann Agric Environ Med; 2019 Jun; 26(2):203-209. PubMed ID: 31232046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endolysins as antimicrobials.
    Nelson DC; Schmelcher M; Rodriguez-Rubio L; Klumpp J; Pritchard DG; Dong S; Donovan DM
    Adv Virus Res; 2012; 83():299-365. PubMed ID: 22748813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications.
    Donovan DM
    Recent Pat Biotechnol; 2007; 1(2):113-22. PubMed ID: 19075835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Screening, and Characterization of Engineered Phage Endolysins with Extracellular Antibacterial Activity against Gram-Negative Bacteria.
    Sui B; Wang X; Zhao T; Zhen J; Ren H; Liu W; Zhang X; Zhang C
    Appl Environ Microbiol; 2023 Jul; 89(7):e0058123. PubMed ID: 37338346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of bacteriophage lytic proteins against Streptococcus pneumoniae in the chloroplast of Chlamydomonas reinhardtii.
    Stoffels L; Taunt HN; Charalambous B; Purton S
    Plant Biotechnol J; 2017 Sep; 15(9):1130-1140. PubMed ID: 28160380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DUF3380 Domain from a Salmonella Phage Endolysin Shows Potent N-Acetylmuramidase Activity.
    Rodríguez-Rubio L; Gerstmans H; Thorpe S; Mesnage S; Lavigne R; Briers Y
    Appl Environ Microbiol; 2016 Aug; 82(16):4975-81. PubMed ID: 27287318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysis of cells of diverse bacteria by l,d-peptidases of Escherichia coli bacteriophages RB43, RB49 and T5.
    Shadrin VS; Machulin AV; Dorofeeva LV; Chernyshov SV; Mikoulinskaia GV
    J Appl Microbiol; 2021 Jun; 130(6):1902-1912. PubMed ID: 33107183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria.
    Briers Y; Lavigne R
    Future Microbiol; 2015; 10(3):377-90. PubMed ID: 25812461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research Progress on Strategies for Improving the Enzyme Properties of Bacteriophage Endolysins.
    Wang Y; Wang X; Liu X; Lin B
    J Microbiol Biotechnol; 2024 Jun; 34(6):1189-1196. PubMed ID: 38693045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More than a hole: the holin lethal function may be required to fully sensitize bacteria to the lytic action of canonical endolysins.
    Fernandes S; São-José C
    Mol Microbiol; 2016 Oct; 102(1):92-106. PubMed ID: 27328857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of modular bacteriophage endolysins from Myoviridae phages OBP, 201φ2-1 and PVP-SE1.
    Walmagh M; Briers Y; dos Santos SB; Azeredo J; Lavigne R
    PLoS One; 2012; 7(5):e36991. PubMed ID: 22615864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered phage enzymes against drug-resistant pathogens: a review on advances and applications.
    Hassannia M; Naderifar M; Salamy S; Akbarizadeh MR; Mohebi S; Moghadam MT
    Bioprocess Biosyst Eng; 2024 Mar; 47(3):301-312. PubMed ID: 37962644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteriophage endolysins as novel antimicrobials.
    Schmelcher M; Donovan DM; Loessner MJ
    Future Microbiol; 2012 Oct; 7(10):1147-71. PubMed ID: 23030422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Advantages and Challenges of Using Endolysins in a Clinical Setting.
    Murray E; Draper LA; Ross RP; Hill C
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33920965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to peptidoglycan-degrading enzymes.
    Grishin AV; Karyagina AS; Vasina DV; Vasina IV; Gushchin VA; Lunin VG
    Crit Rev Microbiol; 2020 Nov; 46(6):703-726. PubMed ID: 32985279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.